Evidence map›Paper›PMID 36680026›Full record

ArticleVaccines2023

Adverse Reactions after Booster SARS-CoV-2 Vaccination Have Less Impact on Antibody Response than after Basic Vaccination Scheme.

Andrea Kanizsai, Laszlo Zavori, Tihamer Molnar, Margit Tőkés-Füzesi, Zoltan Szalai, Janos Berecz, Reka Varnai, Zoltan Peterfi, Attila Schwarcz, Peter Csecsei

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Andrea KanizsaiDepartment of Dentistry, Medical School, University of Pecs, 7624 Pecs, Hungary.
Laszlo ZavoriSalisbury NHS Foundation Trust, Salisbury SP2 8BJ, UK.ORCID 0000-0002-1715-4167
Tihamer MolnarDepartment of Anaesthesiology and Intensive Care, Medical School, University of Pecs, 7624 Pecs, Hungary.
Margit Tőkés-FüzesiDepartment of Laboratory Medicine, Szigetvár Hospital, 7900 Szigetvár, Hungary.
Zoltan SzalaiDepartment of Internal Medicine, Szigetvár Hospital, 7900 Szigetvár, Hungary.
Janos BereczSzigetvár Hospital, 7900 Szigetvár, Hungary.
Reka VarnaiDepartment of Primary Health Care, Medical School, University of Pecs, 7624 Pecs, Hungary.ORCID 0000-0001-8440-3955
Zoltan PeterfiDepartment of Infectology, 1st Depertment of Internal Medicine, Medical School, University of Pecs, 7624 Pecs, Hungary.ORCID 0000-0001-9658-153X
Attila SchwarczDepartment of Neurosurgery, Medical School, University of Pecs, 7624 Pecs, Hungary.
Peter CsecseiDepartment of Neurosurgery, Medical School, University of Pecs, 7624 Pecs, Hungary.
University of Pecs · HUSalisbury NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is known that adverse reactions following SARS-CoV-2 vaccinations show a positive correlation with the subsequent antibody titer. However, it is not clear how the adverse reactions following the booster vaccination are related to the antibody levels that can be measured after a 3rd dose. The primary goal of this study was to investigate whether the adverse reactions following the booster vaccination show a correlation with subsequent antibody levels.

methodsAdverse reactions occurring within 7 days after the 3rd vaccination were recorded and the anti-SARS-CoV-2 spike protein immunoglobulin (Ig) level in the venous blood was measured on post-vaccination 14th, 60th and 120th days.

resultsA total of 218 volunteers were included in the study. MAIN

findings(i) The adverse reactions that appeared after the booster dose did not show a positive correlation with the subsequent antibody level, except a correlation in the case of fever; (ii) there were more symptomatic patients in the group receiving heterologous booster vaccine, (iii) fever after the 2nd dose was independently associated with a reduction in the likelihood of COVID-19 positivity after the booster dose.

conclusionNo adverse reactions, but fever showed a correlation with the antibody level after the booster SARS-CoV-2 vaccine.

Indexed as

adverse reactionsbooster vaccinationSARS-CoV-2

Identifiers

PMID36680026
PMCPMC9864400
OpenAlexW4316466723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.